Citius Oncology (CTOR)

Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York.Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.

• YTD Return

  CTOR-90.95%
  S&P 500+24.05%

• 1-Year Return

  CTOR-90.93%
  S&P 500+31.08%

• 3-Year Return

  CTOR-90.19%
  S&P 500+49.29%

• 5-Year Return

  CTOR-90.19%
  S&P 500+49.29%